ANEBULO PHARMACEUTICALS, INC. Increase (Decrease) in Prepaid Expense and Other Assets
ANEBULO PHARMACEUTICALS, INC. (ANEB) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$967.11 thousand for the 9-month period ending 2022-03-31, per its 10-Q filed 2022-05-11.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2022-05-11
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2022-03-31 was -$254.14K, a 145.16% decline year-over-year.
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2021-12-31 was -$337.72K.
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2021-09-30 was -$375.25K, a 981.30% decline year-over-year.
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2021-06-30 was $1.08M.
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2021 was $1.67M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$254.14K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-11 | -$591.86K derived: sum of 2 quarters · filed 2022-05-11 | -$967.11K 10-Q · filed 2022-05-11 | $109.08K derived: sum of 4 quarters · filed 2022-05-11 |
| 2021-12-31 | -$337.72K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-11 | -$712.97K 10-Q · filed 2022-02-11 | $363.22K derived: sum of 3 quarters · filed 2022-02-11 | $926.03K derived: sum of 4 quarters · filed 2022-05-11 |
| 2021-09-30 | -$375.25K 10-Q · filed 2021-11-12 | $700.94K derived: sum of 2 quarters · filed 2021-11-12 | $1.26M derived: sum of 3 quarters · filed 2022-05-11 | $1.25M derived: sum of 4 quarters · filed 2022-05-11 |
| 2021-06-30 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-22 | $1.64M derived: sum of 2 quarters · filed 2022-05-11 | $1.63M derived: sum of 3 quarters · filed 2022-05-11 | $1.67M 10-K · filed 2021-09-22 |
| 2021-03-31 | $562.81K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-11 | $549.08K derived: sum of 2 quarters · filed 2022-05-11 | $591.66K 10-Q · filed 2022-05-11 | |
| 2020-12-31 | -$13.72K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-11 | $28.86K 10-Q · filed 2022-02-11 | ||
| 2020-09-30 | $42.58K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |